留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

靶向肿瘤微环境的紫杉醇前药研究进展

程丹,  许幼发,  傅志勤,  陈建明

downloadPDF
文章导航 > 药学实践与服务  > 2018 >  36(1): 1-8
程丹, 许幼发, 傅志勤, 陈建明. 靶向肿瘤微环境的紫杉醇前药研究进展[J]. 药学实践与服务, 2018, 36(1): 1-8. doi: 10.3969/j.issn.1006-0111.2018.01.001
引用本文: 程丹, 许幼发, 傅志勤, 陈建明. 靶向肿瘤微环境的紫杉醇前药研究进展[J]. 药学实践与服务, 2018, 36(1): 1-8. doi: 10.3969/j.issn.1006-0111.2018.01.001
shu
CHENG Dan, XU Youfa, FU Zhiqin, CHEN Jianming. Research progress on tumor-targeting paclitaxel prodrugs[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(1): 1-8. doi: 10.3969/j.issn.1006-0111.2018.01.001
Citation: CHENG Dan, XU Youfa, FU Zhiqin, CHEN Jianming. Research progress on tumor-targeting paclitaxel prodrugs[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(1): 1-8. doi: 10.3969/j.issn.1006-0111.2018.01.001
shu

靶向肿瘤微环境的紫杉醇前药研究进展

doi: 10.3969/j.issn.1006-0111.2018.01.001
  • 1.

    第二军医大学药学院药剂学教研室, 上海 200433

  • 2.

    福建中医药大学药学院, 福建 福州 350122

  • 3.

    第二军医大学药学院药剂学教研室, 上海 200433;福建中医药大学药学院, 福建 福州 350122;天津天士力集团有限公司, 天津 300402

Research progress on tumor-targeting paclitaxel prodrugs

  • 1.

    School of Pharmacy, Second Military Medical University, Shanghai 200433, China

  • 2.

    School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China

  • 3.

    School of Pharmacy, Second Military Medical University, Shanghai 200433, China;School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China;Tasly Group Co. Ltd., Tianjin 300402, China

  • 摘要: 紫杉醇前药（paclitaxel prodrugs）的设计是一种提高药物制剂成药性、降低其毒副作用、增强抗肿瘤效果的有效手段。随着对前药研究的深入，利用肿瘤过表达的受体、酶、转运蛋白、谷胱甘肽及活性氧自由基以及肿瘤组织弱酸性及低氧环境等作为靶标进行的紫杉醇靶向性前药的研究已取得极大进展。综述近年来以肿瘤微环境特殊的病理与生理特征为靶标的紫杉醇前药的研究进展。
    Abstract: Paclitaxel is a natural compound with efficient broad-spectrum antitumor activity. However, the clinical application has been limited owing to the undesirable drawbacks, such as the poor water-solubility, cardiovascular toxicity and neurotoxicity. The design of paclitaxel prodrugs is an effective measure which can improve the drug's druggability, alleviate its toxicity adverse effect and enhance its antitumor effect. With the in-depth research of prodrugs, tumor-targeting paclitaxel prodrugs which using the excessive receptors, specific enzymes, transporters, reactive oxide species, glutathione in tumor tissues as well as acidosis and hypoxia in tumors as specific targets, have made great progress. The relevant literature about paclitaxel prodrugs were reviewed in this paper, which targeted to the specific pathological and physiological features of tumor microenvironment in recent years.
  • [1] Wani M C, Taylor H L, Wall M E, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia.[J]. J Amer Chem Soc, 1971, 93(9):2325-2327.
    [2] Yusuf RZ, Duan Z, Lamendola DE, et al. Paclitaxel resistance:molecular mechanisms and pharmacologic manipulation[J]. Curr Cancer Drug Targets, 2003,3(1):1-19.
    [3] Scripture CD, Figg WD, Sparreboom A. Paclitaxel chemotherapy:from empiricism to a mechanism-based formulation strategy[J]. Ther Clin Risk Manag, 2005,1(2):107-114.
    [4] Wang Y, Li X, Wang L, et al. Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery[J]. Int J Nanomed, 2011,6:1497-1507.
    [5] Webster L, Linsenmeyer M, Millward M, et al. Measurement of cremophor EL following taxol:plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype[J]. JNCI, 1993, 85(20):1685-1690.
    [6] Chervinsky DS, Brecher ML, Hoelcle MJ. Cremophor-EL enhances taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell line[J]. Anticancer Res, 1993, 13(1):93-96.
    [7] 张珏, 吕加国, 朱驹. 抗肿瘤药物紫杉醇的化学研究进展[J]. 中国新药杂志, 2006,15(3):178-181.
    [8] Meerum Terwogt JM, ten Bokkel Huinink WW, Schellens JH, et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel.[J]. Anticancer Drugs, 2001,12(4):315-323.
    [9] Tr dan O, Galmarini CM, Patel K, et al. Drug Resistance and the Solid Tumor Microenvironment[J]. JNCI, 2007,99(19):1441-1454.
    [10] Misra S, Hascall VC, Markwald RR, et al. Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer[J]. Front Immunol, 2015,6:201.
    [11] Shahbaz M, Ruliang F, Xu Z, et al. mRNA expression of somatostatin receptor subtypes SSTR-2, SSTR-3, and SSTR-5 and its significance in pancreatic cancer[J]. World J Surg Oncol, 2015,13:46.
    [12] Barar J, Kafil V, Majd MH, et al. Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells[J]. J Nanobiotechnol, 2015,13:26.
    [13] Huo M, Zhu Q, Wu Q, et al. Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy[J]. J Pharm Sci-US, 2015, 104(6):2018-2028.
    [14] Zhong Y, Goltsche K, Cheng L, et al. Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo[J]. Biomaterials, 2016, 84:250-261.
    [15] Alaoui AE, Saha N, Schmidt F, et al. New Taxol(paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy[J]. Bioorg Med Chem, 2006, 14(14):5012-5019.
    [16] Satsangi A, Roy SS, Satsangi RK, et al. Design of a paclitaxel prodrug conjugate for active targeting of an enzyme upregulated in breast cancer cells[J]. Mol Pharm, 2014, 11(6):1906-1918.
    [17] Li N, Cai H, Jiang L, et al. Enzyme-Sensitive and Amphiphilic PEGylated Dendrimer-Paclitaxel Prodrug Based Nanoparticles for Enhanced Stability and Anticancer Efficacy[J]. ACS Appl Mater Interfaces, 2017,9(8),6865-6877.
    [18] 樊健, 俞光荣. 葡萄糖转运蛋白1与恶性肿瘤相关性的研究进展[J]. 中国肿瘤生物治疗杂志, 2010,17(2):232-236.
    [19] Liu DZ, Sinchaikul S, Reddy PV, et al. Synthesis of 2'-paclitaxel methyl 2-glucopyranosyl succinate for specific targeted delivery to cancer cells[J]. Bioorg Med Chem Lett, 2007, 17(3):617-620.
    [20] 常彬霞, 貌盼勇. 谷胱甘肽S转移酶的研究进展及其与肿瘤的相关性[J]. 解放军医学杂志, 2012,37(8):838-842.
    [21] Ushio-Fukai M, Nakamura Y. Reactive oxygen species and angiogenesis:NADPH oxidase as target for cancer therapy[J]. Cancer Lett, 2008,266(1):37-52.
    [22] Jiang Y,Wang X,Liu X, et al. Enhanced antiglioma efficacy of ultrahigh loading capacity paclitaxel prodrug conjugate self-assembled targeted nanoparticles[J]. ACS Appl Mater Interfaces, 2017, 9(1):211-217.
    [23] Luo C, Sun J, Liu D, et al. Self-Assembled Redox Dual-Responsive Prodrug-Nanosystem Formed by Single Thioether-Bridged Paclitaxel-Fatty Acid Conjugate for Cancer Chemotherapy[J]. Nano Lett, 2016, 16(9):5401-5408.
    [24] Yang LV, Castellone RD, Dong L. Targeting Tumor Microenvironments for Cancer Prevention and Therapy[M]. InTech, 2012:1811-1814.
    [25] Ling L, Du Y, Ismail M, et al. Self-assembled liposomes of dual paclitaxel-phospholipid prodrug for anticancer therapy[J]. Int J Pharm, 2017, 526(1-2):11-22.
    [26] 杜征臻, 张琰, 叶金海,等. 聚己内酯-紫杉醇高分子前药的合成及性能研究[J]. 化学学报, 2015, 73(4):349-356.
    [27] Chen L, Endler A, Shibasaki F. Hypoxia and angiogenesis:regulation of hypoxia-inducible factors via novel binding factors.[J]. Experimental & Molecular Medicine, 2009, 41(12):849-857.
    [28] Damen EW, Nevalainen TJ, van den Bergh TJ, et al. Synthesis of novel paclitaxel prodrugs designed for bioreductive activation in hypoxic tumour tissue[J]. Bioorg Med Chem, 2002, 10(1):71-77.
    [29] Wang J, Luo T, Li S, et al. The powerful applications of polyunsaturated fatty acids in improving the therapeutic efficacy of anticancer drugs[J]. Expert Opin Drug Deliv, 2012,9(1):1-7.
    [30] Kuznetsova L, Chen J, Sun L, et al. Syntheses and evaluation of novel fatty acid-second-generation taxoid conjugates as promising anticancer agents[J]. Bioorg Med Chem Lett, 2006,16(4):974-977.
    [31] Bouvier E, Thirot S, Schmidt F, et al. A new paclitaxel prodrug for use in ADEPT strategy[J]. Org Biomol Chem,2003,1(19):3343-3352.
    [32] Nawa A, Tanino T, Luo C, et al. Gene directed enzyme prodrug therapy for ovarian cancer:could GDEPT become a promising treatment against ovarian cancer?[J]. Anticancer Agents Med Chem, 2008, 8(2):232-239.
  • [1] 沈洁, 黄飞, 张星杰, 姚建忠.  双模抗肿瘤光敏剂二氢卟吩e6-偕氟尿嘧啶的合成和生物活性 . 药学实践与服务, 2024, 42(1): 18-23. doi: 10.12206/j.issn.2097-2024.202306030
    [2] 周容睿, 魏艳平, 陈威, 丁倩倩, 王金鑫, 祖先鹏.  补骨脂二氢黄酮甲醚的药理活性及肝毒性研究进展 . 药学实践与服务, 2023, 41(8): 465-471. doi: 10.12206/j.issn.2097-2024.202204031
    [3] 孟祥庆, 李丽华, 王宏瑞, 贾丹, 贾敏.  基于网络药理学和反向分子对接的西红花抗肿瘤作用机制研究 . 药学实践与服务, 2023, 41(3): 160-167, 196. doi: 10.12206/j.issn.2097-2024.202206066
    [4] 温萍, 张俊平.  隐丹参酮及其衍生物抗肿瘤活性研究进展 . 药学实践与服务, 2023, 41(4): 207-211. doi: 10.12206/j.issn.2097-2024.202208090
    [5] 王子妍, 张晓慧, 芮明忠, 周敏, 傅晋翔.  细胞间隙连接在多发性骨髓瘤SP细胞生物学行为中的作用 . 药学实践与服务, 2022, 40(4): 326-334. doi: 10.12206/j.issn.1006-0111.202105104
    [6] 董家潇, 金永生, 曹莺.  黄芩素抗肿瘤作用及其机制研究新进展 . 药学实践与服务, 2021, 39(1): 9-12, 43. doi: 10.12206/j.issn.1006-0111.202004030
    [7] 张晶, 顾永卫, 武鑫.  适配体C2min介导的可靶向2种前列腺癌基因的递送系统 . 药学实践与服务, 2020, 38(1): 47-51,66. doi: 10.3969/j.issn.1006-0111.201906038
    [8] 韩凌, 孙治国, 鲁莹.  抗肿瘤药物纳米粒载体的制备材料、包载药物及修饰方法 . 药学实践与服务, 2018, 36(4): 307-312,350. doi: 10.3969/j.issn.1006-0111.2018.04.005
    [9] 成念, 赵文萃, 张琦, 王艳萍, 韩丹, 肖轩昂.  用疏水改性的白及多糖制备载紫杉醇纳米粒并对其表征 . 药学实践与服务, 2017, 35(1): 48-53. doi: 10.3969/j.issn.1006-0111.2017.01.012
    [10] 施赛健, 张文, 厉廷有, 庄春林.  抗肿瘤多药耐药微管蛋白调节剂的研究进展 . 药学实践与服务, 2017, 35(5): 385-393,397. doi: 10.3969/j.issn.1006-0111.2017.05.001
    [11] 张悦, 王静, 李铁军.  海带多糖抗肿瘤活性研究进展 . 药学实践与服务, 2016, 34(5): 393-395,473. doi: 10.3969/j.issn.1006-0111.2016.05.003
    [12] 苏瑞强, 李晏, 彭坤, 李洁, 杨全, 杨献文.  海洋拟诺卡菌SCSIO 11492中次生代谢产物的分离及其抗肿瘤活性研究 . 药学实践与服务, 2015, 33(5): 406-410. doi: 10.3969/j.issn.1006-0111.2015.05.006
    [13] 金夕琳, 张洁, 江海龙, 陆一鸣.  蛇毒毒素的抗肿瘤作用及其在医药领域的应用 . 药学实践与服务, 2015, 33(6): 502-504,517. doi: 10.3969/j.issn.1006-0111.2015.06.006
    [14] 孙囡囡, 刘嘉, 郑灿辉, 周有骏.  新型四氢-2-萘醇类化合物的合成、晶体结构及抗肿瘤活性 . 药学实践与服务, 2014, 32(3): 191-194. doi: 10.3969/j.issn.1006-0111.2014.03.007
    [15] 张涛, 王甜甜, 张一凯, 牛春娟, 李令振, 李科.  2-(4-三氟甲基苯基)-4-乙基-呋喃-3-酰胺衍生物的设计、合成及其抗肿瘤活性研究 . 药学实践与服务, 2014, 32(2): 98-101,120. doi: 10.3969/j.issn.1006-0111.2014.02.006
    [16] 王园园, 王鑫, 王义善.  瑞香狼毒提取物尼地吗啉的抗肿瘤研究概况 . 药学实践与服务, 2011, 29(5): 328-330,335.
    [17] 廖洪利, 苏春丽, 王伟新, 杨倩.  抗肿瘤青蒿素衍生物的研究 . 药学实践与服务, 2009, 27(2): 84-86.
    [18] 董环文, 刘超美, 何秋琴, 赵荔华.  斑蝥素及其衍生物的抗肿瘤构效关系研究进展 . 药学实践与服务, 2007, (5): 276-280.
    [19] 王昌林, 周月芬, 李昱.  喜树碱类抗肿瘤药物研究概况 . 药学实践与服务, 2001, (3): 172-174.
    [20] 朱全刚, 魏水易.  抗肿瘤新药紫杉醇 . 药学实践与服务, 1995, (1): 12-14.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3014
  • HTML全文浏览量:  289
  • PDF下载量:  855
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-09-13
  • 修回日期:  2017-10-17

靶向肿瘤微环境的紫杉醇前药研究进展

doi: 10.3969/j.issn.1006-0111.2018.01.001
  • 1. 第二军医大学药学院药剂学教研室, 上海 200433
  • 2. 福建中医药大学药学院, 福建 福州 350122
  • 3. 第二军医大学药学院药剂学教研室, 上海 200433;福建中医药大学药学院, 福建 福州 350122;天津天士力集团有限公司, 天津 300402
  • 收稿日期: 2017-09-13
  • 修回日期: 2017-10-17

摘要: 紫杉醇前药（paclitaxel prodrugs）的设计是一种提高药物制剂成药性、降低其毒副作用、增强抗肿瘤效果的有效手段。随着对前药研究的深入，利用肿瘤过表达的受体、酶、转运蛋白、谷胱甘肽及活性氧自由基以及肿瘤组织弱酸性及低氧环境等作为靶标进行的紫杉醇靶向性前药的研究已取得极大进展。综述近年来以肿瘤微环境特殊的病理与生理特征为靶标的紫杉醇前药的研究进展。

English Abstract

程丹, 许幼发, 傅志勤, 陈建明. 靶向肿瘤微环境的紫杉醇前药研究进展[J]. 药学实践与服务, 2018, 36(1): 1-8. doi: 10.3969/j.issn.1006-0111.2018.01.001
引用本文: 程丹, 许幼发, 傅志勤, 陈建明. 靶向肿瘤微环境的紫杉醇前药研究进展[J]. 药学实践与服务, 2018, 36(1): 1-8. doi: 10.3969/j.issn.1006-0111.2018.01.001
shu
CHENG Dan, XU Youfa, FU Zhiqin, CHEN Jianming. Research progress on tumor-targeting paclitaxel prodrugs[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(1): 1-8. doi: 10.3969/j.issn.1006-0111.2018.01.001
Citation: CHENG Dan, XU Youfa, FU Zhiqin, CHEN Jianming. Research progress on tumor-targeting paclitaxel prodrugs[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(1): 1-8. doi: 10.3969/j.issn.1006-0111.2018.01.001
shu

    全文HTML

参考文献 (32)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计